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Abstract
Background: Amyloid-beta (Aβ) plays a key role in Alzheimer’s disease (AD) pathogenesis, and soluble Aβ
oligomers are more cytotoxic than Aβ fibrils. Recent evidence suggests that Notch signaling is affected by AD and
other brain diseases. Melatonin exerts beneficial effects on many aspects of AD and may protect against myocardial
ischemia via Notch1 signaling regulation. Therefore, we hypothesized that the Notch1 signaling pathway is involved
in the neuroprotective role of melatonin against soluble Aβ1–42.
Methods: An AD rat model was established via repeated intracerebroventricular administration of soluble Aβ1–42.
Melatonin treatment was administered 24 hours prior to Aβ1–42 administration via an intraperitoneal injection. The
effects of melatonin on spatial learning and memory, synaptic plasticity, and astrogliosis were investigated. The
expression of several Notch1 signaling components, including Notch1, the Notch1 intracellular domain (NICD), Hairy
and enhancer of split 1 (Hes1, a downstream effector of Notch), and Musashi1 (a positive regulator of Notch), were
examined using immunohistochemistry, western blotting, and quantitative real-time PCR. In vitro studies were
conducted to determine whether the melatonin-mediated protection against Aβ1–42 was inhibited by DAPT, an
inhibitor of Notch signaling.
Results: Melatonin improved the Aβ1–42-induced impairment in spatial learning and memory, attenuated synaptic
dysfunction, and reduced astrogliosis. Melatonin also ameliorated the effects of Aβ1–42 on Notch1, NICD, Hes1, and
Musashi1. The in vitro studies demonstrated that DAPT effectively blocked the neuroprotective effect of melatonin
against Aβ1–42.
Conclusions: These findings suggest that melatonin may improve the soluble Aβ1–42-induced impairment of spatial
learning and memory, synaptic plasticity, and astrogliosis via the Musashi1/Notch1/Hes1 signaling pathway.
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Background
Alzheimer’s disease (AD) is the most prevalent cause of
dementia in older individuals, and it comprises an irre-
versible and progressive neurodegenerative disorder. AD
is characterized by the formation of extracellular amyl-
oid plaques and intracellular neurofibrillary tangles [1].
The amyloid-beta (Aβ) peptide comprises the main com-
ponent of amyloid plaques. Aβ1–42 accumulation in the
brain plays a crucial role in AD pathogenesis and has
been proposed as a trigger for AD onset and progression
[2, 3]. Over the previous 15 years, substantial evidence
has suggested that soluble Aβ oligomers (AβOs) play
pivotal roles in the synaptic dysfunction, neurodegenera-
tion, neuroinflammation, and cognitive deficits present
in AD [4, 5]. Moreover, AβOs are attractive targets for
therapeutics and diagnostics because of their early and
unifying pathological appearance [5–7].
Notch signaling is an evolutionarily conserved pathway
that plays an important role in central nervous system
development. Recent studies have demonstrated that the
Notch1 signaling pathway regulates neurogenesis, neur-
onal networks, synaptic plasticity, and learning and
memory in adult brains [8, 9]. The central component of
Notch1 signaling is the Notch1 receptor protein, a
single-pass transmembrane protein that maintains an
inactivated state without ligand binding [10]. Following
ligand binding, the Notch1 receptor is activated and the
Notch1 intracellular domain (NICD) is released into the
cytosol. The NICD subsequently translocates to the nu-
cleus and regulates its target genes, such as Hairy and
enhancer of split (HES) [11]. HES belongs to the basic
helix–loop–helix (bHLH) family of transcription factors
and plays regulatory roles in neuronal function and
morphology [11]. Hes1 is one of seven members of the
HES gene family and is activated by notch signaling. In
addition, the neural RNA-binding protein Musashi1
plays a key role in the activation of Notch1 signaling by
inhibiting the translation of the Notch1 inhibitor Numb
[12]. Recently, the Notch1 signaling pathway has been
demonstrated to participate in aging processes and mul-
tiple age-related neurodegenerative diseases, such as AD
[8, 9]. Notch signaling is reduced in the aged brain, and
Notch dysfunction is closely related to learning and
memory deficits [9]. Furthermore, an important role for
Notch signaling in AD has recently been identified.
Studies have reported that the Notch signaling activity
was decreased in familial AD (FAD) mutations of
Presenilin1, whereas other studies have demonstrated
that Notch signaling was activated in sporadic AD [8].
Thus, the exact functional role of the Notch signaling
pathway in the onset and progression of AD remains un-
clear. Musashi1 comprises a key regulator of Notch1 sig-
naling, and its downstream protein Numb is important
for AD pathogenesis [13]. However, the extent to which
Musashi1 and Notch signaling participate in the mecha-
nisms that underlie AD pathogenesis is unknown.
Melatonin is a lipophilic neurohormone that has
numerous physiological roles, such as a regulator of
circadian rhythms, a protector of mitochondria, an anti-
oxidant and anti-inflammatory agent, and a neuropro-
tectant [14–18]. The beneficial effect of melatonin on
neurodegenerative diseases has been widely investigated.
In AD patients, the melatonin level was significantly de-
creased in the serum and cerebrospinal fluid (CSF), and
could thus serve as an early diagnostic marker [19–21].
Melatonin supplementation may attenuate Aβ accumu-
lation, neurodegeneration, inflammation, and memory
impairment in AD animal models and patients. There-
fore, melatonin and its agonist are considered promising
therapeutic agents for AD treatment [22, 23]. Accumu-
lating data indicate that melatonin exerts its neuropro-
tective role in AD through the regulation of several
signaling pathways, such as PI3/Akt/GSk3β and hemo-
oxygenase-1 [24, 25]. Nevertheless, knowledge regarding
the cellular mechanisms of the neuroprotective effect of
melatonin in AD is lacking. Additional studies are neces-
sary to elucidate the beneficial actions of melatonin as
an AD treatment and to develop pharmaceutical strat-
egies for AD patients. Recently, Yu and colleagues [26]
demonstrated that melatonin protected against myo-
cardial ischemia–reperfusion injury via the modula-
tion of the Notch1/Hes1 signaling pathway. Therefore,
we hypothesize that melatonin exerts its neuroprotec-
tive effect in a soluble Aβ1–42 oligomer-induced AD
animal model through the Musashi1/Notch1/Hes1 sig-
naling pathway.
In the current study, we initially determined the
protective effect of melatonin against soluble Aβ1–42
oligomer-induced neurotoxicity and astrogliosis in the
hippocampus. We subsequently investigated the regula-
tory role of melatonin on Notch1, Hes1, and Musashi1.
Moreover, we determined whether Notch1 pathway in-
hibition abolished the neuroprotective role of melatonin
against soluble Aβ1–42 oligomers by decreasing NICD,
Hes1, and Musashi1 expression in vitro.
Methods
Animals
Adult male Sprague–Dawley (SD) rats that weighed
250–350 g were purchased from Vital River Laboratory
Animal Technology Company (Beijing, China). The rats
were acclimated to the laboratory environment for
1 week prior to use. Timed pregnant SD rats were bred
in the animal facility at Liaoning Medical University, and
the day of vaginal plug detection was designated as embry-
onic day 0.5 (E0.5). All experimental procedures that in-
volved animals were approved by the Animal Ethics
Committee of Jinzhou Medical University and were
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conducted in accordance with the guidelines of the Animal
Care and Use Committee of Jinzhou Medical University.
Aβ1–42 intracerebroventricular administration and
melatonin intraperitoneal injection
Soluble Aβ1–42 oligomers were prepared according to
previously described methods [27, 28]. Briefly, the hu-
man Aβ1–42 peptide (A9810; Sigma-Aldrich, St. Louis,
MO, USA) was dissolved in sterile double-distilled water
(DDW) at a concentration of 200 μmol/L and incubated
at 37 °C for 24 hours. The preparation was centrifuged
at 14,000 × g at 4 °C for 10 minutes. The supernatant
that contained soluble AβOs was collected and stored at
4 °C. The soluble AβOs were used within 24 hours of
preparation.
Melatonin was dissolved in 100 % ethanol to prepare a
0.1 M stock solution and was subsequently diluted to
25 μM with phosphate-buffered saline (PBS).
The detailed protocol for the implantation of guide
cannulas and Aβ administration in the left lateral ven-
tricle of the brain has been described previously. The
rats were placed in a stereotaxic apparatus (model
51600; Stoelting, Wood Dale, IL, USA) following deep
anesthetization with 10 % chloral hydrate (300 mg/kg,
intraperitoneal (i.p.) injection). The incised area was dis-
infected with 75 % ethanol, and a hole was drilled
through the left side of the skull. A microdialysis guide
cannula (CMA12 Elite microdialysis probe; CMA
Microdialysis AB, Solna, Sweden) was implanted in the
left cerebral lateral ventricle (coordinates from Bregma:
AP = –0.7 mm, ML = +1.7 mm, and DV = −4.0 mm) ac-
cording to the atlas by Paxinos and Franklin (2000) [29].
The cannula was secured to the skull using screws and
dental cement. Three days after the operation, the rats
were randomly divided into four groups (n = 10–14/
group): control (Ctrl, vehicle injection), Aβ1–42 (Aβ,
intracerebroventricular (i.c.v.) injection), melatonin (Mel,
i.p. injection), and Aβ1–42 plus melatonin (Aβ +Mel,
i.c.v. and i.p. injections).
For the melatonin-treated groups, the rats received
500 mg/kg body weight of melatonin (in 25 % ethanol)
via i.p. injection for 16 continuous days between 13:30
and 16:00 hours. The 25 % ethanol solution was used as
the control. For the Aβ1–42 injection groups, awake
and freely moving rats were injected with 80 μmol/L
of Aβ1–42, freshly diluted with DDW, in a 5 μl vol-
ume 1 day after the melatonin injection. Aβ1–42 was
injected every other day for a total of eight injections using
a Hamilton microsyringe (Hamilton, GR, Switzerland) at
an infusion rate of 1 μl/min for 5 minutes. Following the
injection, the injection needle was maintained in place for
an additional 2–3 minutes to prevent reflux. The same
volume of DDW was used as the control.
The detailed timeline of the Aβ1–42 i.c.v. administration,
melatonin i.p. injections, and completion of the Morris
Water Maze (MWM) test is schematically depicted in
Fig. 1.
Morris Water Maze test
Beginning on day 8 of melatonin and Aβ1–42 administra-
tion, the rats (n = 10–14/group) were tested in the
MWM as described previously with several modifica-
tions (Fig. 1) [28, 30]. Briefly, the test was performed in
a circular water pool (diameter 120 cm and height
40 cm) over a 9-day period. The rats underwent four
trials per day with a 10-minute intertrial interval. The
circular pool was filled with water to a depth of 25 cm,
and the temperature was maintained at 24 ± 2 °C. The
maze was divided into four quadrants: northeast (NE),
northwest (NE), southeast (SW), and southwest (SW).
A visible submerged platform (5 cm2) was placed in
the NE quadrant for days 1–3, and a submerged plat-
form was placed in the SW quadrant for days 4–8
with spatial cues located in the room. The platform
was removed on day 9 for the probe trial. Data were
collected and analyzed using a video tracking system
(ANY-maze Video Tracking Software; Stoelting Co.
Wood Dale, IL, USA). The rats were habituated 1 day
prior to training with a 120-second swim session in
the pool without a platform.
For the first 3 days, the rats were trained to find the
visible platform. The platform was placed in the NE
quadrant, and a visible sign was located opposite the
platform quadrant. In each trial, all rats were given
120 seconds to find the platform. If the rats found the
platform, they were allowed to sit on it for 15 seconds.
The rats that failed to find the platform within 120 sec-
onds were guided to the platform and allowed to sit on
it for 15 seconds.
For acquisition testing, the rats were tested for 5 con-
secutive days with a hidden platform. The platform was
placed in the SW quadrant and submerged 2 cm below
the water surface. The other procedures were the same
as the procedures used in the first 3 days. Performance
was measured by the escape latency, path efficiency,
swim speed, and trace for each session.
For probe testing, the platform was removed from the pool
on day 9, and the rats were allowed 120 seconds to search
for the absent platform prior to removal from the water.
Their performances were recorded and analyzed for the time
spent in the target quadrant (where the platform was lo-
cated during the hidden platform training), the number of
entries into the target quadrant, and the swim trace.
Primary neuronal cultures
Primary hippocampal neuron cultures were prepared
from day 18 timed pregnant SD rats as described
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previously with modifications [31]. Briefly, the pregnant
rats were deeply anesthetized, and the embryos were re-
moved from the uterus. The hippocampi were dissected
and placed in ice-cold Hank’s balanced salt solution
(HBSS; Invitrogen). After being cut into small pieces, the
hippocampal tissue was digested with 0.25 % trypsin–
ethylenediaminetetraacetic acid (EDTA) for 5 minutes at
37 °C. The digestion was terminated by the addition of
Minimum Essential Media (MEM; Invitrogen) that con-
tained 10 % fetal bovine serum (FBS). The hippocampal
tissue was then mechanically triturated into a single-cell
suspension in MEM with a fire-polished sterile Pasteur
pipette and centrifuged at 1,000 × g for 5 minutes at
room temperature (RT). The neurons were resuspended
in MEM supplemented with 5 % FBS, 5 % horse serum
(HS), 2 % B27, 2 mM glutamine, and 1 % penicillin/
streptomycin (P/S; Invitrogen). The neuronal suspen-
sions were subsequently plated on poly-D-lysine-coated
24-well plates with circular glass coverslips or 60 mm
tissue culture dishes at a density of 3 × 104 cells/cm2.
The cultures were maintained at 37 °C in a humidified
5 % CO2 incubator (Heratherm 240i; Thermo Scientific,
USA). To inhibit the proliferation of glial cells, 2 μM
cytosine arabinoside (AraC) was added to the cultures
after 2 days. To assess the changes in astrocytes, the
primary neurons were cultured without AraC. The
neurons were fed every 3 days by removing half of
the old media and adding the same volume of fresh
culture media. The cultures were used for experi-
ments on culture day 5.
Cell viability assay (MTT)
For dose-dependent experiments, hippocampal neurons
were treated with soluble Aβ1–42 at concentrations of 0,
25, 50, 100, or 500 nM for 24 hours or with melatonin
at concentrations of 0, 5, 10, 50, or 100 μM for 26 hours.
Concentrations of 100 nM for Aβ1–42 and 50 μM for
melatonin were selected for the other in-vitro experi-
ments. To verify the neuroprotective effect of melatonin
against Aβ1–42 at the selected dosages, neurons were
exposed to vehicle, Aβ1–42, melatonin, or Aβ1–42 plus
melatonin under the same conditions used in the
dose-dependent experiments. The cell viability assay
was conducted using an MTT kit (ST316; Beyotime
Biotechnology, China) according to the manufacturer’s
instructions.
Drug treatment for hippocampal neurons
On day 5, the primary neurons were divided into six
groups: a control group (Ctrl) treated with vehicle; an
Aβ1–42 group (Aβ) treated with Aβ1–42 for 24 hours
at a final concentration of 100 nM; a melatonin group
(Mel) treated with melatonin for 26 hours at a final
concentration of 50 μM; an Aβ1–42 plus melatonin
group (Aβ +Mel) treated with 100 nM Aβ1–42 and
50 μM melatonin; a Aβ1–42 plus melatonin and DAPT
group (Aβ +Mel + D) with a final DAPT (a γ-secretase
inhibitor) concentration of 5 μM; and a DAPT group
(DAPT) with a final concentration of 5 μM.
Western blot analysis
Following deep anesthetization, the animals were rapidly
decapitated and the brains were removed from the skull.
The hippocampi were dissected and processed for pro-
tein extraction immediately or after storage at –80 °C.
For the primary hippocampal neurons, the cells were
rinsed with PBS after treatment and collected for protein
extraction. The hippocampal tissue and primary neurons
from various groups were homogenized in radio-
immunoprecipitation assay (RIPA) buffer (P0013B;
Beyotime, China) using sonication. The samples were
cleared using centrifugation for 5 minutes at 4 °C. The
protein concentration was determined using a bicincho-
ninic acid (BCA) protein assay kit (Bio-Rad, Hercules,
Fig. 1 Schematic illustrating the timeline for drug administration and completion of the MWM. i.p. intraperitoneal injection, i.c.v.
intracerebroventricular administration
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CA, USA). An equal amount of total protein (30 μg)
from each sample was separated by SDS-PAGE and
subsequently transferred to a polyvinylidene difluoride
(PVDF) membrane (Millipore). The membranes were
blocked in a blocking solution that contained 0.1 M
TBST (Tris-buffered saline with Tween 20) and 0.1 %
bovine serum albumin (BSA) for 2 hours at RT. The
membranes were subsequently incubated with different
primary antibodies diluted in the same blocking solution
overnight at 4 °C. The following antibodies were used:
glial fibrillary acidic protein (GFAP) (1:2000, 556327;
BD), full-length Notch1 (1:1000, sc-6015; Santa Cruz
Biotechnology), NICD (1:1000, val1744; Cell Signaling
Technology), Hes1 (1:1000, D6P2U; Cell Signaling
Technology), and Musashi1 (1:1000, ab52865; Abcam).
After three washes with 0.1 % TBST, the membranes
were incubated with a horseradish peroxidase (HRP)-
conjugated anti-rabbit secondary antibody or anti-mouse
IgG (1:2000; Jackson lmmunoResearch Laboratories) at
RT for 2 hours. Immunoreactive bands were detected
using an Enhanced Chemiluminescence Plus kit (32132;
Thermo Scientific, USA). The images were captured
with a UVP BioSpectrum Imaging System (UVP, Upland,
CA, USA). All membranes were reprobed with a β-actin
antibody (1:2000, A2066; Sigma) as an internal control.
The relative intensity of each protein was measured
using VisionWorks LS analysis software (UVP, LLC,
Upland, CA, USA). The percent change in the protein
intensity was calculated relative to the vehicle control in-
cluded in each experiment.
Immunohistochemistry
Rats were transcardially perfused with 4 % parafor-
maldehyde (PFA) in 0.1 M PBS (pH 7.4) under deep
anesthesia. The brains were dissected and post-fixed
in 4 % PFA for 48 hours at 4 °C. After fixation, the
brains were equilibrated in 25 % sucrose in PBS for
48 hours at 4 °C and subsequently cut into 30 μm-thick
coronal sections using a vibratome (Leica VT1200S; Leica
Microsystems, Germany). The sections were stored in
PBS with 0.01 % NaN3 at 4 °C until further use.
The brain sections were mounted on glass slides and
dried at RT. For antigen retrieval, the sections were in-
cubated in 0.01 M citric acid with a pH of 6.0 at 100 °C
for 15 minutes and subsequently washed with TBS (PBS
containing 0.1 % Triton-X100) three times for 5 minutes
per wash. For primary neurons, the cells were rinsed
with PBS and fixed with 4 % PFA in PBS for 30 minutes
at 4 °C and subsequently washed three times with PBS
for 5 minutes per wash. The tissue sections or cells were
blocked in 3 % normal donkey serum (NDS) with
0.3 % TritonX-100 in TBST for 60 minutes at RT and
subsequently incubated in primary antibody overnight
in 3 % NDS and 0.3 % Tween-20 in TBS at 4 °C.
The following primary antibodies were used: GFAP
(1:2000, 556327; BD), SNAP25 (1:2000, 111011; Synaptic
System, Germany), Synaptophysin (1:2000, 611880; BD
Biosciences), Notch1 (1:1000, sc-6015; Santa Cruz
Biotechnology), NICD (1:1000, ab8925; Abcam), Hes1
(1:1000, D6P2U; Cell Signaling), Musashi1 (1:1000,
ab52865; Abcam), βIII-tubulin (1:1000, ab18207; Abcam),
and MAP2 (1:800, NB600-1372; Novus biologicals). After
rinsing, the tissue sections were incubated with a biotinyl-
ated donkey-anti-mouse secondary antibody or rabbit IgG
in 1.5 % NDS for 60 minutes at RT and subsequently
immersed in 0.3 % H2O2 for 30 minutes at RT to block
endogenous peroxidases. After three washes with TBS,
the sections were incubated with solutions from the
Vectastain Elite ABC kit (Vector Laboratories) ac-
cording to the manufacturer’s instructions. The sig-
nals were visualized using a TSA Plus Fluorescence
Kit (Cyanine 3 or Fluorescein kit; PerkinElmer, Waltham,
MA, USA). For primary neurons, the cells were incu-
bated with a donkey-anti-mouse secondary antibody
or rabbit Cyanine 3-conjugated IgG for 2 hours at RT
after washing with TBS. The tissue sections and cells
were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) (1:2000; Invitrogen) and mounted with coverslips
using fluorescent mounting medium (Dako, Carpinteria,
CA, USA). Images were captured with a fluorescence
microscope (DMI4000B; Leica Microsystems, Wetzlar,
Germany). In the control experiments, the primary
antibody was omitted. All images were obtained under
identical settings and analyzed using ImageJ software
(NIH).
RNA isolation and quantitative real-time PCR analysis
Total RNA was isolated from freshly dissected hippo-
campal tissue or primary hippocampal neurons using
TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions. The RNA quantity and quality were
calculated using A260/A280 readings from a NanoDrop
(2000C; Thermo Scientific). cDNA was synthesized using
5 μg of total RNA and the SuperScript® III First-
Strand Synthesis System (Invitrogen) with random
hexamer primers. Quantitative real-time PCR (qPCR)
was performed using an Applied Biosystems 7500 Fast
Real-Time PCR System (Applied Biosystems, Carlsbad,
CA, USA) and MicroAmp Fast 96-well reaction plates
sealed with MicroAmp optical adhesive film. The
amplification reactions were performed with SYBR-
Green Master Mix (Invitrogen) in a 25 μl reaction
volume. All reactions were performed at 50 °C for
2 minutes and 95 °C for 2 minutes followed by 40 cy-
cles of 95 °C for 15 seconds and 60 °C for 30 seconds.
The data were analyzed with 7500 Fast Software v2.3.
All reactions were performed in triplicate with three
animals per group. The glyceraldehyde 3-phosphate
Zhang et al. Alzheimer's Research & Therapy  (2016) 8:40 Page 5 of 18
dehydrogenase (GAPDH) gene expression levels were
used as an internal control. The relative gene expres-
sion was calculated via the 2–ΔΔCt method. The fol-
lowing primers were used: Notch1, forward 5′-CGC
ACA AGG TGT CTT CCA G-3′ and reverse 5′-AGT
AGT TGA GTG TGC GGC-3′ (143 bp); Hes1, for-
ward 5′-TGG AAT AGC GCT ACC GAT CAC-3′
and reverse 5′-GTT GAC TGG GGT AG-3′ (243 bp);
and GAPDH, forward 5′-CTA CCC ACG GCA AGT
TCA AC-3′ and reverse 5′-CCA GTA GAC TCC ACG
ACATAC-3′.
Golgi-Cox staining and spine density analysis
Golgi-Cox staining was performed using the FD Rapid
GolgiStain Kit (FD Neurotechnologies, Ellicott City, MD,
USA) according to the manufacturer’s protocol. Follow-
ing deep anesthetization, the rats were decapitated and
the brains were removed from the skull. The brains were
cut into three coronal blocks, immersed in an impregna-
tion solution for 2 weeks at RT, and subsequently trans-
ferred to solution C for 48 hours at RT in the dark.
They were cut into 100 μm-thick sections using a vibra-
tome (Leica VT1200S; Leica Microsystems, Germany).
The sections were mounted on gelatin-coated slides with
solution C. After drying at RT, the sections were im-
merged in a mixture that contained one part solution D,
one part solution E, and two parts Milli-Q water for
10 minutes. After washing with Milli-Q water, the sec-
tions were dehydrated in graded alcohol solutions,
cleared in xylene, and coverslipped. Images for neurons
in the dentate gyrus (DG) and CA1 and CA3 regions
were obtained with an automated upright microscope
(DM6000 B; Leica). The number of spines on the pri-
mary branches of basal dendrites were counted using
Neurolucida software 10 (MBF Bioscience, Williston,
VT, USA).
For the quantitative analysis, three independent sec-
tions from each animal were randomly selected. After
the images were obtained, 10 neurons from each rat for
a total of three rats per group were analyzed. To deter-
mine the spine density, the spines on three basal den-
drites from a single neuron were counted and the
average number of spines per 10 μm segment was
calculated.
Statistical analysis
All experiments were independently repeated at least
three times. The data are expressed as the mean ±
standard deviation. The statistical analysis was con-
ducted with SPSS 16.0 software (IBM, Somers, NY,
USA) using a one-way analysis of variance (ANOVA)
followed by Bonferroni post-hoc tests. For the escape
latency and swim path efficiency in the MWM test,
the data were analyzed using a two-way repeated-
measures ANOVA followed by LSD post-hoc tests for
multiple group comparisons. The statistical signifi-
cance level was set to p < 0.05.
Results
We initially investigated whether melatonin prevented
the spatial learning and memory impairments induced
by repeated soluble Aβ1–42 i.c.v. injections using the
MWM test. To assess the spatial learning ability, the
rats had to find a hidden platform during 5 consecu-
tive days of acquisition training. The results of a two-
way repeated ANOVA indicated that the time to find
the platform decreased over the 5 consecutive training
days (F(4, 40) = 68.622, p < 0.001). The main effect of
treatment on the escape latency was not significant
(F(3, 30) = 2.919, p = 0.050); however, the results indi-
cated that the Aβ group tended to take longer to
reach the platform on days 6–8 compared with the
control rats. Furthermore, the Aβ +Mel group tended
to take less time to reach the platform on days 6–8
compared with the Aβ group (Fig. 2a). The path effi-
ciency significantly increased over the 5 consecutive
training days (F(4, 40) = 15.186, p < 0.001). There was a
significant effect of treatment on the path efficiency
(F(3, 30) = 3.062, p < 0.05). The swimming path of the
Aβ group tended to be less efficient on days 6–8
compared with the control group. The swimming
path of the Aβ +Mel group tended to be more effi-
cient on days 6–8 compared with the Aβ group
(Fig. 2a, b). These findings suggest that the melatonin
treatment prevented the soluble Aβ1–42-induced im-
pairment in spatial learning.
After acquisition training, the platform was removed
and reference memory was assessed using a probe trial.
The Aβ1–42 i.c.v.-injected rats spent less time in the tar-
get quadrant and completed fewer platform crossings
compared with the control rats. However, the Aβ1–42
rats treated with melatonin spent more time in the tar-
get quadrant and completed more platform crossings
compared with the Aβ1–42-injected rats (Fig. 2c, d). The
Aβ1–42-injected rats swam randomly with little or no
preference for the previous platform location compared
with the control rats. However, the Aβ1–42 rats treated
with melatonin swam more in the previous platform lo-
cation compared with the Aβ1–42-injected rats (Fig. 2e).
These findings indicate that pretreatment with mela-
tonin prevented the soluble Aβ1–42-induced reference
memory impairment.
The swim speeds during the acquisition training and
probe trial were not significantly different among the
treatment groups (data not shown), which suggests the
differences in spatial learning and reference memory
were not the result of differences in the swim speed.
During the visible platform trials on days 1–3, there
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were no differences in the latency to reach the platform
among the groups (data not shown).
To investigate the role of melatonin treatment on
Aβ1–42-induced astrogliosis, we examined the expression
of GFAP, a marker of reactive astrocytes, using immuno-
histochemistry. The GFAP expression in the Aβ1–42-
injected rats was significantly increased in the DG
and CA1 region compared with the control group
(Fig. 3a, c, d). The GFAP expression was also
increased in the CA1 region of the Aβ group com-
pared with the control group; however, the difference
was not significant (Fig. 3b, d). The GFAP expression
in all three hippocampal regions of the Aβ +Mel
group was significantly decreased compared with the
Aβ group, and there were no significant differences
between the Aβ +Mel and control groups (Fig. 3a–d).
For the melatonin groups, the GFAP expression in all
three hippocampal regions was not significantly
Fig. 2 Melatonin improved spatial learning and reference memory in soluble Aβ1–42-injected rats. a Average escape latency for rats searching for
the hidden platform over 5 consecutive training days. b Average swimming path efficiency of rats searching for the hidden platform over 5
consecutive training days. c Average swimming time of rats in the target quadrant during the probe trial. d Average passing times of rats in the
target quadrant during the probe trial. e Swimming paths of rats during the probe trial. Large red circle, water maze pool; small red circle, platform
location. s second, Ctrl control group, Aβ Aβ1–42-injected group, Mel melatonin-injected group, Aβ +Mel dual Aβ1–42 and melatonin-injected group. *p
< 0.05 compared with control rats; #p < 0.05 and ##p < 0.01 compared with Aβ1–42-injected rats
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different compared with the control group (Fig. 3a–
d). To quantitatively verify the protective effect of
melatonin on Aβ1–42-induced astrocyte activation, we
performed a western blot analysis of hippocampal tis-
sue. The results confirmed that the GFAP expression
was significantly increased in the Aβ1–42-injected group
compared with the control group and was significantly
decreased in the Aβ +Mel group compared with the
Aβ group (Fig. 3e, f ). The GFAP expression levels
were similar between the rats injected with melatonin
Fig. 3 Melatonin reduced astrogliosis in soluble Aβ1–42-injected rats. a Representative images of immunofluorescent staining for GFAP in the
dentate gyrus (DG) of the hippocampus. b Representative images of immunofluorescent staining for GFAP in the CA1 region of the hippocampus.
c Representative images of immunofluorescent staining for GFAP in the CA3 region of the hippocampus. d Statistical analysis of immunofluorescent
staining for GFAP in the DG and the CA1 and CA3 regions. e Representative western blot images for GFAP in the hippocampus. f Statistical analysis of
the relative intensity of GFAP immunoreactive bands from hippocampal tissue samples. Scale bar = 100 μm. *p < 0.05 and **p < 0.01 compared with
sham-operated rats; #p < 0.05 and ##p < 0.01 compared with Aβ1–42-injected rats; ^p < 0.05 compared with melatonin-injected rats. DAPI 4′,6-diamidino-
2-phenylindole, GFAP glial fibrillary acidic protein, Ctrl control group, Aβ Aβ1–42-injected group, Mel melatonin-injected group, Aβ +Mel dual Aβ1–42 and
melatonin-injected group
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alone and the Aβ +Mel rats compared with the con-
trol group (Fig. 3e, f ).
We determined whether melatonin protected against
Aβ1–42-induced synaptotoxicity in the hippocampus
under our experimental conditions. Golgi-Cox staining
indicated that the spine density of basal dendrites was
substantially reduced in the neurons of the DG, CA1,
and CA3 regions of the Aβ group compared with the
control group (Fig. 4a, b). The spine density was signifi-
cantly increased in all three hippocampal regions of the
Aβ +Mel group compared with the Aβ group; however,
the spine density in the CA3 region did not reach the
same level identified in the control group (Fig. 4a, b). In
the melatonin groups, the spine density was decreased
in the DG and the CA3 region compared with the con-
trol group; however, there was no significant difference
in the CA1 region compared with the control group
(Fig. 4a, b). To verify these findings, we examined the
expression of the presynaptic proteins SNAP25 and
synaptophysin using immunohistochemistry. The results
were consistent with the Golgi-Cox staining data. The
expression levels of SNAP25 and synaptophysin were
Fig. 4 Melatonin restored the dendritic spine number and synaptic density in Aβ1–42-injected rats. a Representative images of Golgi-Cox staining
of dendritic spines in the dentate gyrus (DG) and the CA1 and CA3 regions of the hippocampus. b Statistical analysis of the average number of
Golgi-Cox stained dendritic spines in the DG and the CA1 and CA3 regions. c Representative images of immunofluorescent staining for SNAP25
in the DG and the CA1 and CA3 regions of the hippocampus. d Statistical analysis of immunofluorescent staining for SNAP25. e Representative
images of immunofluorescent staining for synaptophysin in the DG and the CA1 and CA3 regions of the hippocampus. f Statistical analysis of
immunofluorescent staining for synaptophysin. Scale bar = 100 μm. *p < 0.05 and **p < 0.01 compared with sham-operated rats; #p < 0.05 and
##p < 0.01 compared with Aβ1–42-injected rats. Ctrl control group, Aβ Aβ1–42-injected group, Mel melatonin-injected group, Aβ +Mel dual Aβ1–42
and melatonin-injected group, SYTO synaptophysin, DAPI 4′,6-diamidino-2-phenylindole
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significantly decreased in the DG and the CA1 and CA3
regions of the Aβ group compared with the control
group (Fig. 4c–f ). The reduction in SNAP25 expression
induced by Aβ was completely blocked by melatonin
treatment in all three hippocampal areas of the Aβ +
Mel group, and the reduction in synaptophysin expres-
sion induced by Aβ was completely abolished by mela-
tonin treatment in the DG and the CA3 region of the
Aβ +Mel group (Fig. 4c–f ). Melatonin treatment alone
did not affect the expression of SNAP25 or synaptophy-
sin in the three hippocampal regions compared with the
control group, with the exception of SNAP25 expression
in the CA1 region (Fig. 4c–f ). These findings suggest
that melatonin protected against the soluble Aβ1–42-
induced synaptotoxic effect in the hippocampus under
our experimental conditions.
To determine whether the Notch1 signaling pathway
participated in the protective effect of melatonin against
Aβ-induced astrogliosis and synaptotoxicity in the
hippocampus, we examined the NICD expression using
immunohistochemistry. The expression of NICD was
significantly decreased in the hippocampal DG and the
CA1 and CA3 regions of the Aβ1–42 rats compared with
the control rats (Fig. 5a–d). However, the decrease in
the NICD expression was completely blocked in the DG
and the CA3 region and partially blocked in the CA1 re-
gion of the Aβ +Mel rats compared with the control
and Aβ groups (Fig. 5a–d). There were no obvious dif-
ferences in the NICD expression in the DG or the CA1
or CA3 region of the Mel group compared with the con-
trol group (Fig. 5a–d). To quantitatively analyze the
Notch1 and NICD expression, western blot analysis was
performed with anti-Notch1 and anti-NICD antibodies.
The expression levels of full-length Notch1 (Notch1),
the Notch1 transmembrane fragment (NTMF), and NICD
were significantly decreased in the Aβ1–42-injected rats
compared with the control rats (Fig. 5e–h). However, the
decrease in the Notch1 and NTMF expression was
prevented completely and the decrease in the NICD ex-
pression was prevented partially in the Aβ +Mel treat-
ment group compared with the control and Aβ groups
(Fig. 5e–h). Melatonin treatment alone did not signifi-
cantly affect the expression of Notch1, NTF, or NICD in
the hippocampus compared with the control group
(Fig. 5e–h). Notch1 gene expression was examined using
qPCR. The results were consistent with the western blot-
ting data (Fig. 5i). These findings suggest that melatonin
treatment blocked the effect of soluble Aβ1–42 on Notch1
expression and activation.
We investigated whether other components of Notch1
signaling, including Hes1 (a downstream target of
Notch1) and Musashi1 (a positive regulator of Notch1
signaling), contributed to the protective effect of mela-
tonin against Aβ1–42. We initially examined the effects
of melatonin and Aβ on the Hes1 expression using west-
ern blot analysis. Compared with the control group, the
Hes1 expression was significantly decreased in the Aβ
group; however, it was similar to the controls in the Aβ
+Mel group (Fig. 6a, b). The Hes1 gene expression was
also decreased in the Aβ group compared with the con-
trol group; however, the difference was not significant
(Fig. 6c). In the Mel and Aβ +Mel groups, the Hes1 gene
expression was significantly increased compared with
the Aβ or control groups (Fig. 6c). We also investigated
the Musashi1 expression using immunohistochemistry
and western blotting. The Musashi1 expression was sig-
nificantly decreased in the DG and the CA1 and CA3 re-
gions of the Aβ group compared with the control group,
and the reduction was completely inhibited in the DG of
the Aβ +Mel group (Fig. 6d–g). Our western blotting re-
sults confirmed that the Musashi1 expression was sig-
nificantly decreased in the hippocampus of the Aβ
group compared with the control group, and this reduc-
tion was completely prevented in the Aβ +Mel group
(Fig. 6h, i). Melatonin treatment alone did not exert a
significant effect on the Musashi1 expression (Fig. 6h, i).
These findings suggest that melatonin exerts a protective
effect against Aβ1–42-induced astrogliosis and synapto-
toxicity through the regulation of Hes1 and Musashi1
expression.
To provide more direct evidence for the protective ef-
fect of melatonin against Aβ1–42-induced neurotoxicity
and astrogliosis via the modulation of the Notch1 signal-
ing pathway, in vitro studies were conducted. Neuronal
toxicity in primary hippocampal cultures was assessed
using a cell viability assay. We initially assessed the
dose-dependent effects of a 24-hour Aβ1–42 treatment
and 26-hour melatonin treatment on neuronal toxicity
and neuronal protection, respectively. Neurons exhibited
a dose-dependent decrease in the cell viability following
Aβ1–42 exposure, and 100 nM of Aβ1–42 was the lowest
dosage to induce a significant reduction in neuronal sur-
vival (Fig. 7a). Melatonin exhibited a dose-dependent
neuroprotective effect, and 50 μM was the minimum ef-
fective dose (Fig. 7b). We further assessed the neuropro-
tective effect of melatonin (50 μM, 26 hours) against
Aβ1–42 (100 nM, 24 hours) in primary hippocampal
neuronal cultures. Aβ1–42 induced a significant reduction
in the cell viability compared with the control cells, and
the cell viability was substantially increased in the Aβ +
Mel-treated neurons compared with the Aβ-treated cells
(Fig. 7c). Melatonin treatment alone caused a significant
increase in the cell viability compared with the control
cells (Fig. 7c).
To confirm whether the neuroprotective effect of
melatonin occurs via Notch1 signaling pathway regula-
tion, we used DAPT, a γ-secretase inhibitor, to inhibit
notch1 signaling. Using immunohistochemistry, Aβ1–42
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Fig. 5 Melatonin upregulated the expression of Notch1 and Notch1 intracellular domain (NICD) in soluble Aβ1–42-injected rats. a Representative images of
immunofluorescent staining for NICD in the dentate gyrus (DG) of the hippocampus. b Representative images of immunofluorescent staining for NICD in
the CA1 region of the hippocampus. c Representative images of immunofluorescent staining for NICD in the CA3 region of the hippocampus. d Statistical
analysis of immunofluorescent staining for NICD. e Representative western blot images for Notch1 in the hippocampus. f Statistical analysis of the relative
intensity of Notch1 immunoreactive bands. g Representative western blot images for NICD in the hippocampus. h Statistical analysis of the relative
intensity of NICD immunoreactive bands. i Notch1 gene expression in the hippocampus by qPCR. Scale bar= 100 μm. *p< 0.05 and **p< 0.01 compared
with sham-operated rats; #p< 0.05 and ##p< 0.01 compared with Aβ1–42-injected rats. Ctrl control group, Aβ Aβ1–42-injected group, Mel melatonin-injected
group, Aβ+Mel dual Aβ1–42 and melatonin-injected group, DAPI 4′,6-diamidino-2-phenylindole, NTMF Notch1 transmembrane fragment
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Fig. 6 Melatonin increased Hes1 and Musashi1 expression in soluble Aβ1–42-injected rats. a Representative western blot images for Hes1 in the
hippocampus. b Statistical analysis of the relative intensity of Hes1 immunoreactive bands. c Hes1 gene expression in the hippocampus analyzed
by qPCR. d Representative images of immunofluorescent staining for Musashi1 in the dentate gyrus (DG) of the hippocampus. e Representative
images of immunofluorescent staining for Musashi1 in the CA1 region of the hippocampus. f Representative images of immunofluorescent
staining for Musashi1 in the CA3 region of the hippocampus. g Statistical analysis of immunofluorescent staining for Musashi1. h Representative
western blot images for Musashi1 in the hippocampus. i Statistical analysis of the relative intensity of Musashi1 immunoreactive bands.
Scale bar = 100 μm. *p < 0.05 and **p < 0.01 compared with sham-operated rats; #p < 0.05 and ##p < 0.01 compared with Aβ1–42-injected
rats. Ctrl control group, Aβ Aβ1–42-injected group, Mel melatonin-injected group, Aβ + Mel dual Aβ1–42 and melatonin-injected group,
DAPI 4′,6-diamidino-2-phenylindole
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significantly decreased the expression of βIII-tubulin
(axonal marker) and MAP2 (dendritic marker) in the
primary cultured hippocampal neurons compared with
the control cells (Fig. 8a–d). The expression of βIII-
tubulin and MAP2 was significantly upregulated in the
Aβ +Mel-treated cells compared with the Aβ-treated
cells (Fig. 8a–d). These findings are consistent with our
in vivo findings. However, the βIII-tubulin and MAP2
expression was significantly reduced in the Aβ +Mel +
DAPT-treated neurons compared with the Aβ +Mel-
treated neurons and was not significantly different com-
pared with the Aβ-treated cells (Fig. 8a–d). The βIII-
tubulin and MAP2 expression was also significantly re-
duced in the DAPT-treated neurons compared with the
control group (Fig. 8a–d). These findings suggest that
the neuroprotective effect of melatonin against Aβ1–42
occurs via the Notch1 signaling pathway.
We also verified the inhibitory effect of DAPT on the
Notch1 signaling pathway. In primary neuronal cultures,
immunohistochemistry and western blotting results
indicated that the expression of NICD, Hes1, and
Musashil1 was substantially decreased in the Aβ +
Mel + DAPT-treated cells compared with the Aβ +
Mel-treated cells (Fig. 9a–e). These findings indicate
that DAPT efficiently inhibited Notch1 signaling path-
way activation under our experimental conditions.
Discussion
Our data indicate that the repeated i.c.v. administration
of low doses of soluble Aβ1–42 successfully represented
some aspects of an in vivo AD model in rats. Melatonin
protected against Aβ1–42-induced memory deficits, neu-
roplasticity abnormalities, and astrogliosis under our ex-
perimental conditions. Our findings also indicate that
Notch1 signaling pathway activation by melatonin may
play an important role in its neuroprotection against sol-
uble Aβ1–42.
Increasing evidence suggests that soluble Aβ1–42 oligo-
mers play a central role in AD pathology [4–7]. Recently,
several studies have demonstrated that repeated i.c.v. in-
jections of low doses of Aβ comprised a more effective
and reliable method to induce AD-like learning and
memory impairments [27, 32, 33]. The use of this
method in awake and freely moving animals better re-
sembles AD development compared with a single ad-
ministration of a large dose of Aβ [27, 32, 33]. In our
study, we used this repeated Aβ administration method
with modifications to establish an in vivo AD rat model.
Fig. 7 Effects of Aβ1–42, melatonin, and Aβ1–42 plus melatonin on cell viability in hippocampal neurons. a Dose-dependent effect of Aβ1–42 on cell
viability. *p < 0.05 and **p < 0.01 compared with control cells; ##p < 0.01 compared with 25 nM Aβ1–42-treated cells;
^p < 0.05 and ^^p < 0.01
compared with 50 nM Aβ1–42-treated cells. b Dose-dependent effect of melatonin on cell viability. **p < 0.01 compared with control cells; ##p < 0.01
compared with 5 μM melatonin-treated cells; ^^p < 0.01 compared with 10 μM melatonin-treated cells; @p < 0.05 compared with 50 μM melatonin-
treated cells. c Effect of 50 μM melatonin on cell viability of 100 nM Aβ1–42-treated hippocampal neurons. **p < 0.01 compared with control cells;
##p < 0.01 compared with Aβ1–42-treated cells; ^^p < 0.01 compared with melatonin-treated cells. Ctrl control cells, Aβ Aβ1–42-treated cells,
Mel melatonin-treated cells, Aβ + Mel Aβ1–42 and melatonin-treated cells
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The repeated i.c.v. injection of soluble Aβ1–42 oligomers
successfully produced learning and memory impair-
ments, astrogliosis, and synaptic dysfunction in adult
rats under our experimental conditions (Figs. 2, 3 and 4).
Our study provides additional evidence that the repeated
i.c.v. administration of low-dose soluble Aβ1–42 oligomers
is a simple and reliable approach to develop a rat model
with AD-like cognitive impairments, astrocyte activation,
and synaptic dysfunction.
Melatonin is a multifunctional neurohormone and has
many beneficial effects on AD, including actions as an
antioxidant, neuroprotectant, regulator of mitochondrial
function, and anti-neuroinflammation agent [14, 34, 35].
Recent studies have indicated that melatonin also
Fig. 8 DAPT, an inhibitor of Notch1 signaling, blocked the neuroprotective effects of melatonin against Aβ1–42 in hippocampal neurons.
a Representative images of immunofluorescent staining for βIII-tubulin. b Statistical analysis of immunofluorescent staining for βIII-tubulin.
c Representative images of immunofluorescent staining for MAP2. d Statistical analysis of immunofluorescent staining for MAP2. Scale bar = 100 μm.
**p < 0.01 compared with control cells; ##p < 0.01 compared with Aβ1–42-treated cells; ^^p < 0.01 compared with melatonin-treated cells; @@p < 0.01
compared with Aβ1–42 and melatonin-treated cells. Ctrl control cells, Aβ Aβ1–42-treated cells, Mel melatonin-treated cells, Aβ + Mel Aβ1–42
and melatonin-treated cells, Aβ + Mel + D Aβ1–42, melatonin, and DAPT-treated cells, DAPT DAPT (a γ-secretase inhibitor)-treated cells,
DAPI 4′,6-diamidino-2-phenylindole
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attenuated memory deficits, Aβ accumulation, and im-
pairment of neuroplasticity in a sporadic AD rat
model [18, 36]. Therefore, melatonin is a potential
therapeutic agent for AD prevention and treatment.
Our combined in vivo and in vitro studies confirmed
that melatonin exerts multiple protective actions
against Aβ1–42-induced memory deficits, astrogliosis,
and impaired neuroplasticity. These observations are
consistent with previous studies [18, 36]. In recent
studies, the Notch1 signaling pathway was identified
as an important signaling pathway for normal adult
brain function, as well as in AD and other neurode-
generative diseases [37–39]. The role of Notch1 sig-
naling in the pathogenesis of AD remains
controversial; however, there is evidence that the
modulation of Notch1 signaling may restore neuro-
genesis and cognitive functioning in AD animal
models [40]. Nevertheless, it remains unknown
whether Notch1 signaling is involved in the neuropro-
tective effects of melatonin in AD and other
Fig. 9 DAPT blocked the effects of melatonin on Notch1, Hes1, and Musashi1 in Aβ1–42-treated hippocampal neurons. a Representative images of
immunofluorescent staining for NICD. b Statistical analysis of immunofluorescent staining for NICD. c Representative images and statistical
analysis of western blots for NICD. d Representative images and statistical analysis of western blots for Hes1. e Representative images and
statistical analysis of western blot for Musashi1. Scale bar = 100 μm. **p < 0.01 compared with control cells; #p < 0.05 and ##p < 0.01 compared
with Aβ1–42-treated cells; ^^p < 0.01 compared with melatonin-treated cells; @@p < 0.01 compared with Aβ1–42 and melatonin-treated cells. Ctrl
control cells, Aβ Aβ1–42-treated cells, Mel melatonin-treated cells, Aβ +Mel Aβ1–42 and melatonin-treated cells, Aβ +Mel + D Aβ1–42, melatonin, and
DAPT-treated cells, DAPT DAPT (a γ-secretase inhibitor)-treated cells, DAPI 4′,6-diamidino-2-phenylindole
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neurodegenerative diseases. The Notch1/Hes1 signaling
pathway participates in the melatonin-mediated cardio-
protective effects demonstrated in both in vivo and
in vitro models of myocardial ischemia–reperfusion
injury [26]. In our study, soluble Aβ1–42 suppressed
the expression of Notch1, NTMF, and NICD, an ac-
tive form of Notch1; furthermore, melatonin treat-
ment prevented the Aβ1–42-induced reduction of
Notch1, NTMF, and NICD in vivo and in vitro. These
findings suggest that the Notch1 signaling pathway is
involved in the effects of melatonin on soluble Aβ1–
42-induced memory deficits, impairment of neuroplas-
ticity, and astrogliosis. Additional studies are required
to determine whether Notch1 signaling is involved in
other melatonin-mediated protective effects in AD
and other age-associated neurodegenerative diseases.
The gene and protein expression of Hes1, an essential
downstream effector of Notch1 signaling, was consist-
ently regulated by melatonin in our studies, which pro-
vides further evidence for the regulatory role of
melatonin on Notch1 signaling [11]. Musashi1 com-
prises an important positive regulator of Notch1 signal-
ing by inhibiting the translation of Numb, an inhibitor
of the pathway [12]. Numerous studies have indicated
that Numb may play an important role in the pathogen-
esis and progression of AD [41]; however, the link be-
tween Musashi1 and AD remains unclear. Similar to our
findings for the Notch1 receptor and NICD, the expres-
sion of Hes1 and Musashi1 was decreased by Aβ1–42
treatment, and melatonin completely or partially pre-
vented the effects of Aβ1–42 on Hes1 and Musashi1.
These findings indicate that Hes1 and Musashi1 are in-
volved in the melatonin-mediated protection against
Aβ1–42. In addition to these two factors, the roles of
other Notch signaling components require further
investigation.
The inhibition of γ-secretase inhibits the cleavage of
the Notch1 receptor by blocking Notch1 signal trans-
duction [8, 10]. DAPT, a commonly used γ-secretase
inhibitor, is a powerful inhibitor of Notch1 signaling
[8, 10]. We demonstrated that DAPT treatment com-
pletely blocked the protective effect of melatonin
against Aβ1–42-induced neurotoxicity in vitro. We also
confirmed that DAPT blocked Notch1 signaling by
decreasing NICD, Hes1, and Musashi1 expression.
These findings suggest that the protective effect of
melatonin against Aβ1–42 is dependent on the Musashi1/
Notch1/Hes1 signaling pathway. γ-secretase inhibitors
also directly interfere with Aβ production; thus, another
strategy to block Notch1 signaling will be necessary
to better understand the precise connection between
Notch1 signaling and the neuroprotective effects of
melatonin on AD. Furthermore, Notch1 signaling is
dynamically regulated during brain development and
disease processes via crosstalk with many signaling
pathways. Therefore, additional studies are required
to elucidate the precise mechanism of melatonin in
Notch1 signaling modulation in AD.
Conclusions
The current findings demonstrate that the repeated i.c.v.
administration of low-dose soluble Aβ1–42 oligomers
comprises a simple and effective rat model of AD to in-
vestigate novel therapeutic approaches for AD and their
associated mechanisms. We also demonstrated that the
inhibition of Musashi1/Notch1/Hes1 signaling may play
an important role in soluble Aβ1–42-mediated learning
and memory deficits, neuroplasticity dysfunction, and
astrogliosis. Furthermore, melatonin may protect against
soluble Aβ1–42-mediated learning and memory deficits,
neuroplasticity dysfunction, and astrogliosis through
Musashi1/Notch1/Hes1 signaling pathway activation.
The present study suggests that the Musashi1/Notch1/
Hes1 signaling pathway plays a key regulatory role in
melatonin-mediated effects on AD progression. More-
over, melatonin represents a promising therapeutic agent
against AD and other age-associated neurodegenerative
diseases.
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